Tremfya (guselkumab) / J&J 
Welcome,         Profile    Billing    Logout  
 11 Diseases   40 Trials   40 Trials   2608 News 


«12345678910111213...3738»
  • ||||||||||  Tremfya (guselkumab) / J&J
    Efficacy and Safety of Guselkumab for Crohn (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_1147;    
    P2/3
    Study drug discontinuations in the combined GUS group from Wks 48 to 152 were due to adverse events (AE, n[%]: 6[4.0]), lack of efficacy (2[1.3]), CD-related surgery (1[0.7]), lost to follow-up (4[2.6]), protocol deviation (1[0.7]), pregnancy (1[0.7]), refusal (1[0.7]), and patient withdrawal (9[6.0]). Among all randomized patients in the combined GUS group (including those who did not enter the LTE; primary efficacy analysis set), 54.1% were in CDAI clinical remission, 51.4% were in PRO-2 remission, and 34.7% were in endoscopic response at Wk 144 (Table 1).
  • ||||||||||  Tremfya (guselkumab) / J&J
    Efficacy of Guselkumab in Patients With Moderately to Severely Active Crohn (West Ballroom B) -  Jul 29, 2023 - Abstract #ACG2023ACG_350;    
    Among GUS Wk12 nonresponders, 46.0% were in clinical response by Wk24 (Table). Percentages of Wk12 nonresponders who went on to achieve outcomes at Wk48 in the GUS and UST groups, respectively, were as follows: clinical response, 58.7% and 47.6%; clinical remission, 41.3% and 33.3%; PRO-2 remission, 42.9% and 23.8%; and endoscopic response, 31.7% and 23.8% (Table).
  • ||||||||||  Tremfya (guselkumab) / J&J
    Trial primary completion date:  GRAVITI: A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) -  Jul 22, 2023   
    P3,  N=350, Active, not recruiting, 
    At baseline, for the GUS and PBO groups, respectively, mean absolute number of stools per day were 7.10 and 6.96; stool frequency subscores of 0 or 1 were observed in 10.0% and 9.6%; and mean rectal bleeding subscores were 1.7 and 1.8. Trial primary completion date: Feb 2023 --> Jul 2023
  • ||||||||||  Retrospective data, Review, Journal:  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (Pubmed Central) -  Jul 16, 2023   
    Living systematic reviews offer a new approach to review updating, in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
  • ||||||||||  The Utilization of biological therapy in psoriasis  () -  Jul 3, 2023 - Abstract #WCD2023WCD_6930;    
    Up to 2% of the psoriasis patients received biological treatment. Anti-IL17 was the preferred first- and second-line biologic agent used in Malaysia
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Tremfya (guselkumab) / J&J
    Small molecules, big results! () -  Jul 3, 2023 - Abstract #WCD2023WCD_6906;    
    KEY MESSAGE: Standard-dose guselkumab had a significant and rapid effect for an obese patient with refractory plaque psoriasis involving scalp and fingernail in concomitance with PsA and other comorbidities, and was well-tolerated in patients with LTBI. Over the years, the patient underwent multiple treatments
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
    SARS-CoV-2 infection among patients with psoriasis in Germany  () -  Jul 3, 2023 - Abstract #WCD2023WCD_6896;    
    The majority of patients positive for COVID-19 showed mild symptoms and continued treatment with systemic antipsoriatic drugs. Independently of treatment, long-lasting COVID-19 symptoms were prevalent in about 30x and suggest particular attention in practice
  • ||||||||||  Tremfya (guselkumab) / J&J
    Recurrent Oral Candidiasis In Patient Receiving An IL23 - inhibitor Due To Moderate - Severe Plaque Psoriasis. A Case Report () -  Jul 3, 2023 - Abstract #WCD2023WCD_6888;    
    OBSERVATIONS: We report the case of a 70?year?old female patient with severe plaque psoriasis, who is monitored at our dermatology clinic during treatment with Guselkumab for recurrent episodes of oral candidiasis...Three months after the incident, patient presents a recurrent episode of oral candidiasis treated successfully while has presented one more ever since. KEY MESSAGES: Given the potential of increased risk of oral candidiasis as well as in patients receiving anti interleukin-23 therapies, dermatologists should be attentive to clinical signs of oral candidiasis and be aware of how to manage these cases appropriately, especially for patients with other risk factors for the development of Candida
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J, Cimzia (certolizumab pegol) / Astellas, UCB
    Paradoxical psoriatic alopecia induced by anti-TNF () -  Jul 3, 2023 - Abstract #WCD2023WCD_6859;    
    The other case was induced by certolizumab (multifocal alopecia areata-like subtype) and improved by topical and systemic corticosteroids and treatment switching to guselkumab...However, a prompt diagnosis and treatment is strictly required since, even if only rarely, scarring alopecia may develop. Further studies are required to improve our knowledge about the occurrence of new or as yet un-described emerging adverse events due to new available biological drugs and to identify effective and safe alternative therapeutic options to manage the underlying disease minimizing the risk of paradoxical reactions
  • ||||||||||  Tremfya (guselkumab) / J&J
    Long-term Efficacy of Guselkumab in Patients with Baseline Nail or Scalp Psoriasis: Results from VOYAGE 1&2 through 5 Years () -  Jul 3, 2023 - Abstract #WCD2023WCD_6842;    
    INTRODUCTION: VOYAGE 1&2 compared guselkumab(GUS) with placebo(PBO) or adalimumab(ADA) in moderate-to-severe plaque psoriasis. Complete skin clearance responses to GUS in patients with baseline scalp/nail involvement were consistent with the overall population of GUS-treated patients from VOYAGE 1&2, comparable to GUS-treated patients without scalp/nail involvement at baseline, and maintained through 5 years of GUS treatment
  • ||||||||||  Tremfya (guselkumab) / J&J
    Guselkumab efficacy and safety for moderate-to-severe psoriasis: Real-world experience () -  Jul 3, 2023 - Abstract #WCD2023WCD_6818;    
    Greater proportions of both female and male patients treated with GUS vs ADA at W24 experienced no impact of psoriasis on individual DLQI domains The present study shows our real-world experience with guselkumab confirming its usefulness and safety in the management of plaque psoriasis patients
  • ||||||||||  Tremfya (guselkumab) / J&J
    Exploring the exposure-response relationship of guselkumab in chronic plaque psoriasis: preliminary results () -  Jul 3, 2023 - Abstract #WCD2023WCD_6805;    
    At week 4, a distinction between optimal and suboptimal responders can be made based on guselkumab exposure, allowing timely dose modifications or treatment switch when needed. At steady-state, targeting a guselkumab serum trough concentration of 1.6 ?g/ml may be a viable treatment option in suboptimal responders to prevent underexposure and subsequent suboptimal clinical response
  • ||||||||||  Efficacy of anti-IL17 treatment in patients with moderate-severe plaque psoriasis who had failed IL-23 inhibitors () -  Jul 3, 2023 - Abstract #WCD2023WCD_6789;    
    Immunohistochemistry results within 4 weeks help support the clinical observation of faster psoriasis resolution in IXE-treated patients compared to GUS First two patients prior to switch were receiving Risankizumab while last three were receiving Guselkumab for 7, 10, 5, 5 and 9 months respectively...First three patients switched to Brodalumab while later two to ixekizumab...Therefore we conclude that when patients fail to respond to an IL-23 antagonist, the IL-23/IL-17 axis is not
  • ||||||||||  Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim, Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall, Tremfya (guselkumab) / J&J
    Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice () -  Jul 3, 2023 - Abstract #WCD2023WCD_6721;    
    The three anti-IL-23 therapies assessed are promising, safe and effective options in elderly patients, and there was no significant difference between them. However, more data are needed to confirm our results and to understand their role in the management of this group of patients